Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Therini Bio doses first patients in Phase 1b trial of THN391 for diabetic macular edema treatment

Company Fundamentals
27 May 2026
Not Specified
View Source
Bullish
pluang ai news

Therini Bio has started dosing patients in a Phase 1b trial for THN391, a novel antibody targeting fibrin-driven inflammation in diabetic macular edema (DME). This therapy aims to reduce neuroinflammation and retinal degeneration without affecting blood clotting. The trial will test safety and efficacy across three dose levels, with initial results expected in late 2026. Additionally, Therini is advancing THN622, a bispecific antibody combining anti-fibrin and anti-VEGF actions, potentially improving treatment outcomes for retinal diseases including DME.

More News

ResVR launches AI assistant to revolutionize online homebuying with real-time guidance and insights

ResVR launches AI assistant to revolutionize online homebuying with real-time guidance and insights

ResVR has introduced an AI-powered assistant integrated into its 3D virtual homebuying platform, enabling buyers to navigate, customize, and make decisions with real-time voice interaction. This assistant offers 24/7 support, multi-language accessibi...

Others
Bullish
13 minutes ago
Privia Health expands to New Jersey, partnering with Neurology Group of Bergen County.

Privia Health expands to New Jersey, partnering with Neurology Group of Bergen County.

Privia Health Group, a national physician enablement company, announced its expansion into New Jersey through a partnership with Neurology Group of Bergen County (NGBC), a large neurology practice with 25 clinicians. NGBC will anchor the new Privia M...

Market News
Bullish
1 hour ago
Matlantis integrates AI agent Claude Code to simplify atomistic simulations with natural language commands.

Matlantis integrates AI agent Claude Code to simplify atomistic simulations with natural language commands.

Matlantis has introduced an AI agent integration using Anthropic's Claude Code to its atomistic simulation platform, allowing researchers to create and run simulations via natural language. This innovation removes the scripting barrier in computation...

Others
Bullish
1 hour ago
AsymBio launches Conjugation Toolbox for faster bioconjugate process development in 2-3 months

AsymBio launches Conjugation Toolbox for faster bioconjugate process development in 2-3 months

AsymBio, a biologics CDMO, introduced its Conjugation Toolbox to support customized and scalable process development for next-generation bioconjugates like antibody-drug conjugates (ADCs). This platform offers flexible conjugation methods, including ...

Others
Bullish
1 hour ago
JenaValve names Edward Sarnowski as CTO to lead R&D after FDA approves Trilogy heart valve system

JenaValve names Edward Sarnowski as CTO to lead R&D after FDA approves Trilogy heart valve system

JenaValve Technology, Inc. has appointed Edward Sarnowski as Chief Technology Officer to lead its research and development efforts. This move follows the recent FDA approval of JenaValve's Trilogy Transcatheter Heart Valve System, designed to treat s...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App